Celldex Therapeutics Inc. (CLDX) announced Monday morning that the independent Data Safety and Monitoring Board has recommended that its Phase 3 study of RINTEGA, in patients with newly diagnosed EGFRvIII-positive glioblastoma, be discontinued.
from RTT - Before the Bell http://ift.tt/1p4LOX3
via IFTTT
No comments:
Post a Comment